Affinity labeling of forskolin-binding proteins comparison between glucose carrier and adenylate cyclase  by Pfeuffer, Elke & Pfeuffer, Thomas
Volume 248, number 1,2, 13-17 FEB 07095 May 1989 
Affinity labeling of forskolin-binding proteins 
Comparison between glucose carrier and adenylate cyclase 
Elke Pfeuffer and Thomas Pfeuffer 
Department of Physiological Chemistry, University of Wiirzburg, Medical School, D-8700 Wikzburg. FRG 
Received 15 March 1989 
An ~ZsI]iodoazidosalicylic a id derivative of forskolin was synthesized for identification of the ditetpene’s binding sites 
on the catalytic subunit of adenylate cyclase and on glucose transport proteins. The affinity label was selectively incorpo- 
rated into proteins of M, 4000&60000 in membranes from human erythrocytes and from various other tissues. The iodo- 
azidosalicylic acid derivative also specifically labeled the catalytic moiety of adenylate cyclase from rabbit myocardial 
membranes. However, the structural requirements of the two forskolin-binding sites must be different, since the affinity 
of the photolabel for the glucose carriers is much higher than that for the cyclase catalyst. Furthermore, the label is readily 
competed with by D-glucose and cytochalasin B for its binding site on the glucose carrier but not on adenylate cyclase. 
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1. INTRODUCTION 
For a certain period of time, the hypotensive 
plant constituent forskolin was considered as a 
selective ligand for adenylate cyclases from higher 
organisms. The original suggestion by Seamon and 
Daly [l] was that the diterpene should bind to the 
catalytic portion of that enzyme because a variant 
cell S49 cyc-, devoid of G,, was likewise 
stimulated, although to a lower degree. This was 
finally confirmed by the isolation to homogeneity 
of the enzyme from heart and brain [2-41. 
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Abbreviutions: IASA-forskolin, 3 ‘-iodo-4’-azidosalicylamido- 
ethylamido-7-succinyldeacetylforskolin; SD-forskolin, 7-succi- 
nyldeacetylforskolin; G,, stimulatory guanine nucleotide- 
binding protein of adenylate cyclase; os, a-subunit of G,; C, 
catalytic subunit of adenylate cyclase; Gpp(NH)p, guanylyl 
,&,y-imidotriphosphate; TLC, thin-layer chromatography 
However, recent studies have revealed a specific 
interference of forskolin with other systems, where 
the participation of CAMP was unlikely, e.g. in- 
hibition of carbachol-stimulated uptake of 86Rb+ 
into PC-12 cells, effect on voltage-dependent K+ 
channels in the same cell line and inhibition of the 
insulin-dependent and -independent glucose 
transport in various tissues [5-81. 
Until now forskolin has only been exploited to 
tag covalently the glucose carrier of human 
erythrocytes either by using the diterpene directly 
as a photoaffinity label (of low efficiency [9]) or 
recently via its iodoazido derivative [lo]. This 
analog has been shown to bind to the glucose car- 
rier with even higher affinity than forskolin itself. 
However, no data have been presented thus far on 
the forskolin-binding site of adenylate cyclase. The 
present study describes the synthesis of ~4 novel for- 
skolin photoaffinity label, iodoazidosalicylamido- 
ethylamidosuccinyldeacetylforskolin (IASA-fors- 
kolin) which was exploited for a comparative study 
of the forskolin-binding sites of glucose carrier and 
adenylate cyclase. 
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2. MATERIALS AND METHODS 
2.1. Materials 
4-Azidosalicylic acid N-hydroxysuccinimide ester and 
lodogen were obtained from Pierce; cytochalasin B and 
phenylmethylsulfonyl fluoride were Serva products. 
7Succinyldeacetylforskolin (SD-forskolin) was prepared ac- 
cording to [2]. Na12’I (carrier-free), [~u-‘~P]ATP (600 Ci/mmol) 
and I-fluoro-2,4-dinitro[3,5--‘HIbenzene (lo-30 Ci/mmol) 
were from the Radiochemical Centre, Amersham. All other 
chemicals were of the highest purity available. Mature rabbit 
hearts were from Pel freez, Rogers, As. Membranes therefrom 
were prepared and the complex between catalytic subunit and 
as-protein (Ccu,) of adenylate cyclase was purified according to 
Pfeuffer et al. [2], with the exception that activation was by 
AlFa instead of Gpp(NH)p. Briefly, membranes (20 mg/ml) 
were incubated with 10 mM NaF, lO.uM AlC13, 6 mM MgClz 
for 1 h at 0°C before solubilisation with Lubrol PX as de- 
scribed. Human erythrocyte membranes were prepared as in 
[l l] and human platelet membranes according to [12]. 
2.1.1. Photolysis and SDS-polyacrylamide gel electrophoresis 
Samples incubated with [‘2’I]IASA-forskolin were irradiated 
with a UV lamp (Hanau, type 406 AC) of wavelength 254 nm 
at a distance of 5 cm for 8 min at 4°C. Irradiated samples were 
dissociated in the presence of 1% SDS and 1% fl- 
mercaptoethanol for 2 h at 30°C and run on 4-15% gradient 
polyacrylamide-SDS gels according to Laemmli [13]. Dried gels 
were autoradiographed using Kodak XAR 5 films and Siemens 
Titan 2 HS intensifying screens. Molecular mass standards were 
myosin (200 kDa), ,&galactosidase (116 kDa), phosphorylase 
(97 kDa), bovine serum albumin (67 kDa), ovalbumin 
(45 kDa). Protein was estimated according to Lowry et al. [14] 
or as described by Schultz et al. [l5]. 
2.1.2. Buffers 
Buffer A comprised 10 mM N-morpholinopropanesulfonate 
(pH 7.4), 0.2 mM phenylmethylsulfonyl f uoride, 3 mM ben- 
zamidine, 150 mM NaCl and 1 mM Tween 60; buffer B was 
composed of 5 mM phosphate (pH 8.0). 
2.2. Synthesis of IASA-forskolin 
2.2.1. SD-forskolin N-hydroxysuccinimide ster (1) 
This was prepared according to our previous procedure [2] by 
reacting 50rmol (23 mg) SD-forskolin with 8.6 mg (75 amol) 
N-hydroxysuccinimide and 15.5 mg dicyclohexylcarbodiimide 
(75 pmol) in 1.4 ml anhydrous acetonitrile for 2 h at 22°C. 
Precipitated dicyclohexylurea was removed by centrifugation 
and the supernate containing 1 was immediately reacted with 2 
or stored at 22°C under exclusion of moisture. 
2.2.2. N-Ethylamino(4-azidosalicylamide) (2
20 mg 4-azidosalicylic acid N-hydroxysuccinimide ester 
(75 pmol) were dissolved in 200 ~1 anhydrous dimethylforma- 
mide and 15 ~1 ethylenediamine (225 pmol) added. The mixture 
was left for 2 h at 22°C and the precipitate formed was removed 
by centrifugation and washed with 100 ~1 anhydrous dimethyl 
formamide. The residue was taken up in a minimum amount of 
methanol (containing 1% of acetic acid) and chromatographed 
on a 3 ml silica gel (Kieselgel60, Merck) column using methanol 
14 
as eluant. The major UV-absorbing ninhydrin-positive product, 
2 (TLC on silica sheets using methanol/2% acetic acid as sol- 
vent) was collected, the solvent removed by evaporation and the 
residue taken up in 200 pl absolute dimethyl formamide. 
2.2.3. Azidosalicylamidoethylamido-SD-forskolin (3) 
SD-forskolin N-hydroxysuccinimide ester, 1 (7.6 mg, 
15 pmol), in 540 pl acetonitrile and N-ethylamino(4-azidosali- 
cylamide), 2 (7.5 mg, 41 pmol), in 150~1 dimethyl formamide 
were mixed and left for 24 h at 22°C. Following removal of 
solvents in vacua, the residue was chromatographed on 3 ml 
silicia gel using chloroform/methanol (19: 1) as solvent. The 
photoreactive forskolin derivative was monitored by TLC 
(chloroform/methanol, 9: 1) and the fractions evaporated to 
dryness. The yield of 3 was 5 mg. 
2.2.4. 4-lodoazidosalicylamidoethylamido-SD-forskolin (4) 
5 pl of a 0.5 mM solution of 3 in dimethyl formamide, 50 81 
of a 0.1 mM solution of NaI in water, 10 pl carrier-free Nai2’I 
(1 mCi in 0.1 M NaOH) and 50 ~1 of 100 mM phosphate buffer 
(pH 7.4) were mixed and placed into a glass tube (1 x 7 cm) 
previously coated with 30~8 Iodogen in 100 pl CHCl,. The 
reaction mixture was left for 20 min at 22°C and then transfer- 
red to a glass tube (0.6 x 4 cm) containing 50 pl of a solution 
of sodium bisulfide (20 mg/ml). After 2 min at 22°C the solu- 
tion was extracted twice with 15081 each of water-saturated 
ethyl acetate. The combined extracts were dried with anhydrous 
NazS04 and then evaporated by a stream of N2 using a charcoal 
trap. The residue was taken up in dimethyl formamide to give 
a 0.5 x 10m4 M solution of 4 and kept at 22°C. All manipula- 
tions concerning the azidosalicylic derivative were performed 
under protection from light. 
3. RESULTS AND DISCUSSION 
Fig.1 depicts the route for the synthesis of 
IASA-forskolin. It was synthesized from the com- 
mercially available starting materials, SD- 
forskolin and 4-azidosalicylic acid N-hydroxy- 
succinimide ester. The latter was converted to 
the ethylenediamido derivative which was then 
coupled to the activated SD-forskolin. The 
resulting forskolin derivative could be easily 
iodinated with 12’1 or 1251 in reasonable yields. 
Fig.2 shows the results from an affinity labeling 
experiment with [ ‘251]IASA-forskolin and several 
membrane preparations analysed by SDS gel elec- 
trophoresis. In each case the label identified a 
specific glucose-binding species, since the radioac- 
tivity was drastically displaced by D-glucose (but 
not L-glucose). Unlabeled forskolin (lOO-fold ex- 
cess) was likewise able to compete with the label 
(not shown). While human erythrocyte membranes 
displayed the characteristic broad band ranging 
from 65 to 40 kDa also observed with other labels 
(e.g. [3H]cytochalasin B IS]), the respective pro- 
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Fig.1. Synthesis of [‘251]IASA-forskolin. 
teins in rabbit myocardial and human thrombocyte 
membranes appeared as more discrete bands on 
SDS gels. When compared to other membranes, 
including turkey erythrocyte membranes, human 
red blood cell membranes contain an exceptionally 
large amount of glucose carrier protein. 
Subsequently, we examined [‘251]IASA- 
forskolin with respect o its capacity to serve as an 
affinity label for adenylate cyclase. Fig.3 shows the 
dose-response relationship for [‘271]IASA- 
forskolin in comparison with forskolin and the 
precursor SD-forskolin on activation of 
AIF:-stimulated adenylate cyclase from rabbit 
myocardial membranes. The activated form was 
chosen for stimulation and labeling of that en- 
zyme, since there is ample evidence to show that it 
binds to the diterpene with much higher affinity 
than the basal (unstimulated) form [ 16-181. For 
example, affinity chromatography on immobilized 
forskolin is more efficient with the activated form 
of the enzyme [16]. The latter is considered to 
represent he complex between the catalyst and the 
Gs-protein or its a-subunit [2]. Unlike the purified 
Gr,-complex which does bind to forskolin and 
derivatives, but is not further stimulated, the crude 
species is still susceptible to activation by forskolin 
[2,19]. Fig.3 indicates that the affinity label is 
somewhat less efficient in stimulation of 
AlFZ-activated particulate cyclase than the parent 
compound forskolin but exhibits a similar EC50 
(0.7 vs 0.3 ,uM). In contrast, SD-forskolin is much 
less efficient. 
While forskolin seems to bind to glucose carriers 
and adenylate cyclase with similar affinities, there 
is a significant difference with respect to the 
iodoazido derivative (IASA-forskolin). The latter 
binds to the glucose carrier with even greater af- 
finity (by more than one order of magnitude) than 
the parent compound. The superior affinity of 
IASA-forskolin for the carrier allowed for condi- 
tions suitable for the suppression of nonspecific 
binding, e.g. removal of excess label before 
photolysis by extensive wash steps. 
Due to the much lower abundance of adenylate 
cyclase and as a result of its lower affinity for for- 
skolin and IASA-forskolin, no specific labeling 
1.5 
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Fig.2. Photoaffinity labeling with [‘Z51]1ASA-forskolin of 
membranes from various tissues. Membranes from human 
erythrocytes (20,~g). human platelets (165 pg) and rabbit 
myocardium (205 pg) in buffer A were incubated in the 
presence (+) and absence (-) of 508 mM D-glucose for 25 min 
at 4°C. Thereafter, 5 nM [iz51]IASA-forskolin (200 Ci/mmol) 
was added and the mixture incubated further for 25 min at 4°C 
in the dark. Membranes were then washed three times (2 ml 
each) with buffer A by centrifugation (50000 x g at 4°C for 
5 min). The pellets were dispersed in 150 ~1 buffer A, irradiated 
and analysed by SDS gel electrophoresis as described in section 
2. Molecular masses (in kDa) are indicated on the left for the 
standard proteins. 
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Fig.3. Stimulation of AlFZ-activated adenylate cyclase from 
rabbit myocardial membranes. Rabbit myocardial membranes 
(20 mg/ml, in buffer B) were incubated with 10 mM NaF, 
1OpM AICI,, 6 mM MgClz for 1 h at 0°C and tested for 
adenylate cyclase activity without washing. Treated membranes 
(1OOpg) were incubated in the presence of the indicated 
concentrations of forskolin or derivatives and 0.1 mM 
[~u-~*P]ATP (10 cpm/pmol), 10 mM creatine phosphate, 
20 /g/ml creatine kinase, 5 mM theophylline, 5 mM MgCl2, in 
20 mM Mops buffer (pH 7.4) for 20 min at 30°C and cyclase 
activity measured as described [2]. Vehicle for forskolin and 
Fig.4. Failure of glucose and cytochalasin B to compete for 
forskolin-binding sites on adenylate cyclase. (A) Purified 
Cm, .AlFi complex from rabbit myocardium (0.18 cg = 
0.95 pmol) was incubated with 300 nM [‘251]1ASA-forskolin 
(200 Ci/mmol in lOOr buffer B in the absence (-) and 
presence of 30 PM forskolin (For), 500 mM D-glucose (G) or 
10 ,LJM cytochalasin B (CB) for 10 min at 22°C in the dark. PS, 
protein stain of the same preparation via radioiodination 
according to Greenwood et al. [20]. (B) Human erythrocyte 
membranes (0.3 mg/ml) in buffer A were pretreated without 
(-) and with 30 ,uM forskolin (For), or 500 mM glucose (G) or 
1OpM cytochalasin B (CB) and 5 nM [‘251]1ASA-forskolin. 
Further treatment was as described in the legend to fig.1. 
Samples from (A,B) were irradiated and analysed by SDS gel 
electrophoresis as described in section 2. Molecular masses for 
derivatives was ethanol (2% final). standard proteins are indicated in kDa. 
was observed when crude membranes (e.g. 
myocardial or human platelet membranes) were in- 
spected. Therefore, specific labeling of adenylate 
cyclase could only be achieved using pure or par- 
tially purified preparations. Such an experiment is 
shown in fig.4A for purified AIFT-activated 
myocardial enzyme. Labeling only of the 150 kDa 
catalytic moiety and not of the LY~ portion of the 
enzyme was noted. Furthermore, photoincorpora- 
tion was almost completely abolished by 
simultaneous addition of excess unlabeled for- 
skolin. In contrast to the glucose carrier (fig.4B) 
and in agreement with the failure to affect 
adenylate cyclase activity, the azido label ex- 
perienced no competition at all with D-glucose or 
cytochalasin B. 
One of the benefits in the use of [‘251]IASA- 
forskolin as an affinity label for forskolin-binding 
sites lies in its ease of preparation. It requires only 
the radioiodination of a stable precursor, thus 
avoiding the recurrent multistep preparation of a 
16 
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radiolabeled intermediate which must be coupled 
to the forskolin part of the label [lo]. 
The new affinity label also allows for labeling of 
the glucose transporters in various tissues where 
these proteins occur in much lower concentrations 
as compared to human erythrocyte membranes. In 
the case of the glucose carrier, the higher affinity 
of the label with its rather hydrophobic side chain 
as compared to forskolin is remarkable and con- 
firms the observations made by Wadzinski et al. 
[lo] on a related compound. A similar 
phenomenon has been reported by us recently 
[21,22] with GTP analogs. When looking at 
stimulation of adenylate cyclase via G,, y- 
substituted aryl esters of aryl amidates were shown 
to be much more efficient than short-chain y-alkyl 
esters or the y-fluoridate of GTP. 
Unfortunately, the ‘hydrophobic’ effect (i.e. 
gain in affinity) displayed by the affinity label did 
not apply for the forskolin-binding site of the 
catalytic subunit of adenylate cyclase. However, 
the label can be used to tag specifically this site us- 
ing more purified preparations of the enzyme 
(fig.4A). Sequence information is available for 
glucose carriers [23,24] and will certainly be 
available in the near future for adenylate cyclase as 
well. It will be of interest to determine how the 
respective binding sites may differ between these 
different forskolin-binding proteins, exhibiting 
such diverse functions. 
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